Pan-cancer pervasive upregulation of 3' UTR splicing drives tumourigenesis
© 2022. The Author(s)..
Most mammalian genes generate messenger RNAs with variable untranslated regions (UTRs) that are important post-transcriptional regulators. In cancer, shortening at 3' UTR ends via alternative polyadenylation can activate oncogenes. However, internal 3' UTR splicing remains poorly understood as splicing studies have traditionally focused on protein-coding alterations. Here we systematically map the pan-cancer landscape of 3' UTR splicing and present this in SpUR ( http://www.cbrc.kaust.edu.sa/spur/home/ ). 3' UTR splicing is widespread, upregulated in cancers, correlated with poor prognosis and more prevalent in oncogenes. We show that antisense oligonucleotide-mediated inhibition of 3' UTR splicing efficiently reduces oncogene expression and impedes tumour progression. Notably, CTNNB1 3' UTR splicing is the most consistently dysregulated event across cancers. We validate its upregulation in hepatocellular carcinoma and colon adenocarcinoma, and show that the spliced 3' UTR variant is the predominant contributor to its oncogenic functions. Overall, our study highlights the importance of 3' UTR splicing in cancer and may launch new avenues for RNA-based anti-cancer therapeutics.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
Nature cell biology - 24(2022), 6 vom: 26. Juni, Seite 928-939 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chan, Jia Jia [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
3' Untranslated Regions |
|---|
| Anmerkungen: |
Date Completed 20.06.2022 Date Revised 14.11.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41556-022-00913-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM341410772 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM341410772 | ||
| 003 | DE-627 | ||
| 005 | 20231226011719.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41556-022-00913-z |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1137.xml |
| 035 | |a (DE-627)NLM341410772 | ||
| 035 | |a (NLM)35618746 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chan, Jia Jia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pan-cancer pervasive upregulation of 3' UTR splicing drives tumourigenesis |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.06.2022 | ||
| 500 | |a Date Revised 14.11.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s). | ||
| 520 | |a Most mammalian genes generate messenger RNAs with variable untranslated regions (UTRs) that are important post-transcriptional regulators. In cancer, shortening at 3' UTR ends via alternative polyadenylation can activate oncogenes. However, internal 3' UTR splicing remains poorly understood as splicing studies have traditionally focused on protein-coding alterations. Here we systematically map the pan-cancer landscape of 3' UTR splicing and present this in SpUR ( http://www.cbrc.kaust.edu.sa/spur/home/ ). 3' UTR splicing is widespread, upregulated in cancers, correlated with poor prognosis and more prevalent in oncogenes. We show that antisense oligonucleotide-mediated inhibition of 3' UTR splicing efficiently reduces oncogene expression and impedes tumour progression. Notably, CTNNB1 3' UTR splicing is the most consistently dysregulated event across cancers. We validate its upregulation in hepatocellular carcinoma and colon adenocarcinoma, and show that the spliced 3' UTR variant is the predominant contributor to its oncogenic functions. Overall, our study highlights the importance of 3' UTR splicing in cancer and may launch new avenues for RNA-based anti-cancer therapeutics | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a 3' Untranslated Regions |2 NLM | |
| 700 | 1 | |a Zhang, Bin |e verfasserin |4 aut | |
| 700 | 1 | |a Chew, Xiao Hong |e verfasserin |4 aut | |
| 700 | 1 | |a Salhi, Adil |e verfasserin |4 aut | |
| 700 | 1 | |a Kwok, Zhi Hao |e verfasserin |4 aut | |
| 700 | 1 | |a Lim, Chun You |e verfasserin |4 aut | |
| 700 | 1 | |a Desi, Ng |e verfasserin |4 aut | |
| 700 | 1 | |a Subramaniam, Nagavidya |e verfasserin |4 aut | |
| 700 | 1 | |a Siemens, Angela |e verfasserin |4 aut | |
| 700 | 1 | |a Kinanti, Tyas |e verfasserin |4 aut | |
| 700 | 1 | |a Ong, Shane |e verfasserin |4 aut | |
| 700 | 1 | |a Sanchez-Mejias, Avencia |e verfasserin |4 aut | |
| 700 | 1 | |a Ly, Phuong Thao |e verfasserin |4 aut | |
| 700 | 1 | |a An, Omer |e verfasserin |4 aut | |
| 700 | 1 | |a Sundar, Raghav |e verfasserin |4 aut | |
| 700 | 1 | |a Fan, Xiaonan |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Shi |e verfasserin |4 aut | |
| 700 | 1 | |a Siew, Bei En |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Kuok Chung |e verfasserin |4 aut | |
| 700 | 1 | |a Chong, Choon Seng |e verfasserin |4 aut | |
| 700 | 1 | |a Lieske, Bettina |e verfasserin |4 aut | |
| 700 | 1 | |a Cheong, Wai-Kit |e verfasserin |4 aut | |
| 700 | 1 | |a Goh, Yufen |e verfasserin |4 aut | |
| 700 | 1 | |a Fam, Wee Nih |e verfasserin |4 aut | |
| 700 | 1 | |a Ooi, Melissa G |e verfasserin |4 aut | |
| 700 | 1 | |a Koh, Bryan T H |e verfasserin |4 aut | |
| 700 | 1 | |a Iyer, Shridhar Ganpathi |e verfasserin |4 aut | |
| 700 | 1 | |a Ling, Wen Huan |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Jianbin |e verfasserin |4 aut | |
| 700 | 1 | |a Yoong, Boon-Koon |e verfasserin |4 aut | |
| 700 | 1 | |a Chanwat, Rawisak |e verfasserin |4 aut | |
| 700 | 1 | |a Bonney, Glenn Kunnath |e verfasserin |4 aut | |
| 700 | 1 | |a Goh, Brian K P |e verfasserin |4 aut | |
| 700 | 1 | |a Zhai, Weiwei |e verfasserin |4 aut | |
| 700 | 1 | |a Fullwood, Melissa J |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Wilson |e verfasserin |4 aut | |
| 700 | 1 | |a Tan, Ker-Kan |e verfasserin |4 aut | |
| 700 | 1 | |a Chng, Wee Joo |e verfasserin |4 aut | |
| 700 | 1 | |a Dan, Yock Young |e verfasserin |4 aut | |
| 700 | 1 | |a Pitt, Jason J |e verfasserin |4 aut | |
| 700 | 1 | |a Roca, Xavier |e verfasserin |4 aut | |
| 700 | 1 | |a Guccione, Ernesto |e verfasserin |4 aut | |
| 700 | 1 | |a Vardy, Leah A |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Leilei |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Xin |e verfasserin |4 aut | |
| 700 | 1 | |a Chow, Pierce K H |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Henry |e verfasserin |4 aut | |
| 700 | 1 | |a Tay, Yvonne |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nature cell biology |d 1999 |g 24(2022), 6 vom: 26. Juni, Seite 928-939 |w (DE-627)NLM104898879 |x 1476-4679 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2022 |g number:6 |g day:26 |g month:06 |g pages:928-939 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41556-022-00913-z |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2022 |e 6 |b 26 |c 06 |h 928-939 | ||